Z Factor Ltd, a Cambridge-based drug development company spun out of the University of Cambridge, announced that the first human volunteer was dosed today with ZF874, its novel treatment for alpha-1-antitrypsin deficiency (AATD).
Cambridge Enterprise, University of Cambridge
Cambridge Enterprise exists to help University of Cambridge inventors, innovators and entrepreneurs make their ideas and concepts more commercially successful for the benefit of society, the UK economy, the inventors and the University.
Telephone: +44 (0)1223 760 339
Address :
Hauser Forum 3 Charles Babbage Road Cambridge
Post Code: CB3 0GT
Country: United Kingdom
Website: http://www.enterprise.cam.ac.uk
Membership Type: Cambridge University Department
Cambridge Enterprise offers support to all of the University’s research fields, from science, technology, engineering, maths and medicine to the arts, humanities and social sciences. It is through us that many of the University’s inventions and ideas are protected, licences and consultancy contracts are negotiated, and funding is acquired by start-ups and spin-outs.
There are no Products & Services to display
19-08-2020
Bond180, a provider of technology solutions for primary fixed income markets, has announced completion of a strategic funding round. The round involved follow-on investment from Cambridge Enterprise, joined by technology partners, strategic angels, and venture investors.
21-07-2020
Research England has awarded two grants, totalling £1.5 million, to support two programmes working to dramatically increase the economic value and social impacts derived from university research, both internationally and in the UK. The funds will be administered by the University of Cambridge.
16-07-2020
PharmEnable, a Cambridge-based drug discovery company using advanced medicinal chemistry and AI-enabled approaches to design the next generation of highly complex and specific drug candidate molecules, announces it has closed a £1.8 million seed financing to support its transition into a drug development company.
30-06-2020
Semiconductor company Flusso has raised a $5.7 million Series A funding round to scale up production of the world’s smallest flow sensor. The round was led by existing investor Parkwalk Advisors and new investor Foresight Williams Technology EIS Fund, with participation from Cambridge Enterprise, 24 Haymarket, Martlet, and Cambridge Angels.
03-06-2020
Poro Technologies, the Gallium Nitride (GaN) material technology developer and a recent spin-out from the University of Cambridge, has closed a £1.5 million seed round investment to develop a pilot plant in Cambridge and its first major products. The seed round was co-led by Cambridge Enterprise, the commercialisation arm of the University of Cambridge, and IQ Capital Partners, with the...
08-04-2020
Kalium Health, which aims to transform the lives of patients with kidney disease, announces the completion of a seed investment round. Cambridge Enterprise led the over-subscribed round with participation from Kidney Research UK, Cambridge Angels and Martlet Capital, the investment arm of Marshall of Cambridge Group.
13-03-2020
Ajay Chowdhury has been named Chair of the Board of Cambridge Enterprise. He assumed leadership of the Board in January, overseeing the strategy of Cambridge Enterprise, which is tasked with supporting the commercialisation of the ideas that emerge from the University.
06-03-2020
The University of Cambridge has launched its seventh Enterprise Fund, managed by university spinout fund manager Parkwalk in conjunction with Cambridge Enterprise, the University's Technology Transfer Office.
18-02-2020
Riverlane, Europe’s most advanced quantum computing software developer, has raised £3.25m in seed funding, led by venture capital investors Cambridge Innovation Capital (CIC) and Amadeus Capital Partners, with the participation of Cambridge Enterprise.
13-06-2019
A small consultancy agreement facilitated by Cambridge Enterprise in 2012 led to some surprising results – and a major project that could prove world-changing.
10-06-2019
Researchers from the UK and Spain have identified an eco-friendly solid that could replace the inefficient and polluting fluids used in most refrigerators and air conditioners.
19-04-2019
Cambridge Enterprise, the commercialisation arm of the University of Cambridge, welcomes three new Directors and two new Advisors to its governing body. Together they bring a range of new perspectives to the Board, including representation from the Arts, Humanities and Social Sciences and an international outlook.
01-04-2019
A small consultancy project enabled by Cambridge Enterprise has blossomed over a short space of time into a major new initiative to develop and commercialise greener and more efficient light emitting diodes (LEDs).
12-03-2019
Two of the most innovative US universities, along with their UK counterparts, will meet with the minister and innovation and industrial strategy leaders from UK government today (Monday 25 February).
25-02-2019
Paul Bailey, one of Cambridge’s most influential entrepreneurs and Executive Chairman of Bailey Fisher, has joined Cambridge Enterprise, the commercialisation arm of the University of Cambridge, as an Entrepreneur in Residence.
29-01-2019
Cambridge Enterprise and the Maxwell Centre are jointly hosting the University of Cambridge exhibit at AutoMobili-D 2019, within the North American International Auto Show in Detroit yhis week (14-17 January).
16-01-2019
Morphogen-IX Ltd, a University of Cambridge spin-out biotechnology company focused on the development of bone morphogenetic proteins (BMPs) for the treatment of pulmonary arterial hypertension (PAH), has announced completion of a £18.4 million ($23.2m) round of financing.
19-12-2018
Colorifix, a company that has developed the first commercial biological dyeing process, has raised a Series A round of $3 million from impact and strategic investors with strong links to the fashion industry. The round was led by Challenger 88, with participation from Cambridge Enterprise, H&M CO:LAB (part of H&M Group) and Primera Impact.
18-12-2018
Morphogen-IX Ltd, a biotechnology spin-out from Cambridge Enterprise that is focused on the development of bone morphogenetic proteins (BMPs) for the treatment of pulmonary arterial hypertension (PAH), announced the nomination of its clinical development candidate and initiation of formal preclinical development.
04-12-2018
Pages
There are no events to display
There are no jobs to display
No Blog articles found
